Anesiva Accelerates Its Transition to Specialty Pharma Pain Manageme... ( Company Focuses Operations Update...)

Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company

Date:9/3/2008

Company Focuses Operations, Updates Zingo Launch Progress and Adlea

Registration Strategy

Conference Call Today at 11:30 am ET

SOUTH SAN FRANCISCO, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) announced today that the company will restructure operations to focus on commercial and late-stage product development to accelerate its transition to a specialty pharmaceutical pain management company. The company also provided updates on Zingo launch progress, announced the full enrollment of its Phase 3 Adlea clinical trials and provided an update on its Adlea registration strategy.

"Since joining Anesiva in mid-June, I have conducted an extensive review of our programs, priorities and core competencies, which confirms my confidence in the underlying strength of our assets -- namely our people and pipeline," said Michael L. Kranda, president and CEO. "Based on this review we are refining our strategy and restructuring operations to drive the company toward long-term success."

"We believe these actions will expedite our ability to increase the company's value. Specifically, we will continue to strongly support the commercial growth of our first marketed product Zingo(TM), which we recently launched as an analgesic prior to peripheral IV insertions and blood draws in children ages three to 18, and the timely and comprehensive clinical development and commercialization of Adlea(TM), which is in late-stage clinical development for the management of acute pain following orthopedic surgeries. We also intend to pursue the in-licensing of late-stage products that fit within and strengthen our product portfolio," continued Mr. Kranda.

The company is re
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery
2. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
3. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
4. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
5. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
6. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
7. Anesiva Defines Regulatory Pathway for Adlea with FDA
8. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
9. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
10. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
11. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited

Post Your Comments:

Anesiva Accelerates Its Transition to Specialty Pharma Pain Manageme...( Company Focuses Operations Update...),Health